The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-04 and is reviewed periodically as new material appears.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Acid proteases Neutral proteases involved in type 1 hypersensitivity. Here, it is released by mast cells and causes activation of complement and kinins. This group includes the calpains. Basic proteases (or alkaline proteases)
As a social institution, chattel slavery classes slaves as chattels (personal property) owned by the enslaver; like livestock, they can be bought and sold at will. Chattel slavery was historically a widely accepted form of slavery in many parts of the world, and was practiced in places such as ancient Greece and the Roman Empire, where it was considered a keystone of society. Other examples include the institution of slavery in the Muslim world such as Medieval Egypt, as well as Sub-Saharan Africa, Brazil, the Antebellum United States, and parts of the Caribbean such as Cuba and Haiti. The Iroquois also had practices similar to chattel slavery; the key difference was that captives were held for the stated purpose of "assimilating them into Iroquoian culture". As a result, there were several ways to escape captivity, and the children of those in bondage "became fully part of society". Beginning in the 18th century, a series of abolitionist movements in Europe and the Americas saw slavery as a violation of the slaves' rights as people ("all men are created equal"), and sought to abolish it. Abolitionism encountered extreme resistance but was eventually successful. Several of the states of the United States began abolishing slavery during the American Revolutionary War. After the French Revolution, the government of France abolished slavery in 1794, but Napoleon reintroduced it in 1802 and permanent abolition did not occur until 1848.
== Method == Depending on where the bone graft is needed, a different doctor may be requested to do the surgery. Doctors and physicians that perform bone graft procedures are commonly orthopedic surgeons, otolaryngology head and neck surgeon, neurosurgeons, craniofacial surgeons, oral and maxillofacial surgeons, podiatric surgeons and periodontists, dental surgeons, oral surgeons and implantologists.
Sources: en.wikipedia.org
== History == In 1976, the first Old Chicago taphouse opened in Boulder, Colorado. The first Gordon Biersch Brewery Restaurant was opened in Palo Alto, California on July 6, 1988. The first Rock Bottom restaurant opened in Denver, Colorado in 1991. In 1993, Big River Breweries opened its first location in Chattanooga, Tennessee. Rock Bottom Restaurants, Inc., made an initial public offering in 1994. In 1995, the first ChopHouse opened in Denver, Colorado. Big River Breweries opened the only brewpub at Walt Disney World in 1996. A private management buyout took Rock Bottom Restaurants, Inc. private in 1999. In the same year, Gordon Biersch was acquired by Big River Breweries. In 2000, Rock Bottom Restaurants formed the Rock Bottom Foundation, a 501(c)(3) non-profit entity. Rock Bottom Restaurants laid off about 20% of its corporate staff in 2007 and slowed its growth plans along with ceasing its search for an equity partner. In 2010, Rock Bottom Restaurants and Gordon Biersch Brewery Restaurant Group were acquired by Centerbridge Capital Partners and merged to form CraftWorks Restaurants and Breweries, Inc. On November 1, 2018, CraftWorks announced that it had acquired Logan's Roadhouse and formed Craftworks Holdings. Logan's Roadhouse is a chain of restaurants founded in 1991 in Lexington, Kentucky. The chain's menu includes mesquite-grilled steaks, traditional American fare (sandwiches, soup, salads, and seafood), ice-cold longneck beer, and homemade yeast rolls. On June 12, 2020, Craftworks was purchased by SPB Hospitality for $93 million.
=== Defense against infections === PGLYRP2 plays a limited role in host defense against infections. PGLYRP2-deficient mice are more sensitive to Pseudomonas aeruginosa-induced keratitis and Streptococcus pneumoniae-induced pneumonia and sepsis. However, PGLYRP2-deficient mice did not show a changed susceptibility to systemic Escherichia coli, Staphylococcus aureus, and Candida albicans infections or intestinal Salmonella enterica infection, although the latter was accompanied by increased inflammation in the cecum. Although PGLYRP2 is not directly bacteriolytic, it has antibacterial activity against both Gram-positive and Gram-negative bacteria and Chlamydia trachomatis. Human and mouse PGLYRP2 promote hepatitis B virus (HBV) clearance in vitro in hepatocytes and in HBV-infected mice. PGLYRP2 through its HBV DNA-binding domain recognizes covalently closed circular DNA (cccDNA) of HBV sequestering it in the nucleus and separating it from the cellular viral replication machinery. Additionally, PGLYRP2 suppresses HBV capsid assembly by directly interacting through its PGRP domain with the viral capsid and promoting secretion of the PGLYRP2-HBV capsid complexes.
ester A class of organic and inorganic compounds derived from the reaction of an acid with an alcohol, in which at least one hydroxyl group (–OH) is replaced by an alkoxy group (–O–). Esters have the general formula RCO2R′, where R and R' represent any alkyl or aryl group.
This term can then define the residual enzymatic activity present when the inhibitor is interacting with individual enzymes in the population. However, the inclusion of this term has the added value of allowing for the possibility of activation if the secondary Vmax term turns out to be higher than the initial term. To account for the possibly of activation as well, the notation can then be rewritten replacing the inhibitor "I" with a modifier term denoted here as "X".
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.